Jean-Sebastien Frenel, Jean Zeghondy, Catherine Guérin-Charbonnel, Audrey Mailliez, Elsa Volant, François Poumeaud, Anne Patsouris, Monica Arnedos, Caroline Bailleux, Julie Cabal, Loick Galland, Alexandre de Nonneville, Séverine Guiu, Florence Dalenc, Barbara Pistilli, Thomas Bachelot, Jean-Yves Pierga, Fanny Le Du, François Bocquet, Louis Larrouquere, Delphine Loirat
IMPORTANCE: Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC). OBJECTIVE: To investigate outcomes following TTC treatment in patients with ERBB2-positive MBC who had previously received trastuzumab-deruxtecan. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included all patients with MBC who were treated in 12 French comprehensive cancer centers between August 1, 2020, and December 31, 2022...
April 1, 2024: JAMA Network Open